iifl-logo

Lupin Ltd AGM

1,988
(0.42%)
Sep 11, 2025|12:00:00 AM

Lupin CORPORATE ACTIONS

12/09/2024calendar-icon
12/09/2025calendar-icon
PurposeAGM DateAnnouncement Date
AGM11 Aug 202514 Jul 2025
AGM 11/08/2025 Intimation of the Forty-Third Annual General Meeting of the Company and Record Date for payment of Dividend. Intimation of Record Date for payment of final Dividend, if declared Notice of Forty-Third Annual General Meeting of the Company and Integrated Report for FY 2024-25. (As Per BSE Announcement Dated on: 19/07/2025) Integrated Report for FY 2024-25 - Revised. (As Per BSE Announcement Dated on :23.07.2025) Proceedings of the Forty-Third Annual General Meeting held on August 11, 2025. (As Per BSE Announcement Dated on: 11.08.2025)

Lupin: Related News

Lupin Launches Glucagon Kit in US, Eyes $122 Mn Market

The launch aligns with Lupin’s strategic push into injectables, biosimilars, and inhalation therapies, supported by robust R&D and manufacturing capabilities

12 Aug 2025|11:20 AM
Read More
Top Stocks for Today - 6th August 2025

Here are some of the stocks that may see significant price movement today: Bharti Airtel, Torrent Power, Lupin Limited, etc.

6 Aug 2025|08:29 AM
Read More
Lupin gets USFDA approval for post-eye surgery drug

This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.

2 Jul 2025|11:27 AM
Read More
Top Stocks for Today - 2nd July 2025

Here are some of the stocks that may see significant price movement today: Godrej Properties, SBI Cards, Hyudai India, etc.

2 Jul 2025|06:39 AM
Read More
Lupin Expands US Presence with Launch of Prucalopride Tablets

The tablets will be made at the company’s Goa facility, a site that has previously cleared global regulatory inspections and supports Lupin’s key exports.

27 Jun 2025|10:48 AM
Read More
Lupin Expands to China with Tiotropium Inhaler Deal Amid Rising COPD Cases

The company said this deal fits into its larger strategy of expanding respiratory therapies beyond its home markets.

16 Jun 2025|02:08 PM
Read More
Lupin inks licensing pact with SteinCares for biosimilar

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America.

27 May 2025|10:29 AM
Read More
Top Stocks for Today - 27th May 2025

Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.

27 May 2025|06:36 AM
Read More
Lupin Secures USFDA Approval for Tolvaptan Tablets

The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.

24 Apr 2025|09:39 PM
Read More
Lupin Gets USFDA Nod for Nagpur Injectable Plant After Clean Inspection

The clearance is on the back of a four-day USFDA inspection between June 10 and June 13, 2024.

18 Apr 2025|12:29 AM
Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.